For example, in a phase I study of futibatinib, two partial responses were observed in a cohort of 9 patients with GC, only one of whom had an FGFR2 amplification and the other a FGFR3–TACC3 fusion [88]. The gene discussed is FGFR2; the disease is gastric cancer.